Literature DB >> 15750341

The Src/PLC/PKC/MEK/ERK signaling pathway is involved in aortic smooth muscle cell proliferation induced by glycated LDL.

Hyun-Mi Cho1, Sung Hee Choi, Ki-Chul Hwang, Sue-Young Oh, Ho-Gyung Kim, Deok-Hyo Yoon, Myung-Ae Choi, Soyeon Lim, Heesang Song, Yangsoo Jang, Tae Woong Kim.   

Abstract

Low density lipoproteins (LDL) play important roles in the pathogenesis of atherosclerosis. Diabetes is associated with accelerated atherosclerosis leading to cardiovascular disease in diabetic patients. Although LDL stimulates the proliferation of arterial smooth muscle cells (SMC), the mechanisms are not fully understood. We examined the effects of native LDL and glycated LDL on the extracellular signal-regulated kinase (ERK) pathway. Addition of native and glycated LDL to rat aorta SMCs (RASMCs) stimulated ERK phosphorylation. ERK phosphorylation was not affected by exposure to the Ca2+ chelator BAPTA-AM but inhibition of protein kinase C (PKC) with GF109203X, inhibition of Src kinase with PP1 (5 microM) and inhibition of phospholipase C (PLC) with U73122/U73343 (5 microM) all reduced ERK phosphorylation in response to glycated LDL. In addition, pretreatment of the RASMCs with a cell-permeable mitogen-activated protein kinase kinase (MEK) inhibitor (PD98059, 5 microM) markedly decreased ERK phosphorylation in response to native and glycated LDL. These findings indicate that ERK phosphorylation in response to glycated LDL involves the activation of PKC, PLC, and MEK, but is independent of intracellular Ca2+.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750341

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  12 in total

Review 1.  Therapeutic potential for protein kinase C inhibitor in vascular restenosis.

Authors:  Richard Qinxue Ding; Jerry Tsao; Hong Chai; Daria Mochly-Rosen; Wei Zhou
Journal:  J Cardiovasc Pharmacol Ther       Date:  2010-12-23       Impact factor: 2.457

2.  The integrin alpha2beta1 agonist, aggretin, promotes proliferation and migration of VSMC through NF-kB translocation and PDGF production.

Authors:  Ching-Hu Chung; Kuan-Ting Lin; Chien-Hsin Chang; Hui-Chin Peng; Tur-Fu Huang
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

3.  Delayed and persistent ERK1/2 activation is required for 4-hydroxytamoxifen-induced cell death.

Authors:  Jian-Hua Zhou; David V Yu; Jingwei Cheng; David J Shapiro
Journal:  Steroids       Date:  2007-07-07       Impact factor: 2.668

4.  In skeletal muscle advanced glycation end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs.

Authors:  Angela Cassese; Iolanda Esposito; Francesca Fiory; Alessia P M Barbagallo; Flora Paturzo; Paola Mirra; Luca Ulianich; Ferdinando Giacco; Claudia Iadicicco; Angela Lombardi; Francesco Oriente; Emmanuel Van Obberghen; Francesco Beguinot; Pietro Formisano; Claudia Miele
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

5.  Glucose lowers the threshold for human aortic vascular smooth muscle cell migration: inhibition by protein phosphatase-2A.

Authors:  M Campbell; P Anderson; E R Trimble
Journal:  Diabetologia       Date:  2008-03-14       Impact factor: 10.122

6.  Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis.

Authors:  Kikuo Isoda; Eduardo Folco; M Reza Marwali; Fumitaka Ohsuzu; Peter Libby
Journal:  Atherosclerosis       Date:  2007-12-27       Impact factor: 5.162

7.  Inhibiting low-density lipoprotein glycation ameliorates increased cholesteryl ester synthesis in macrophages and hypercholesterolemia and aortic lipid peroxidation in streptozotocin diabetic rats.

Authors:  Margo P Cohen; Elizabeth A Shea; Van-Yu Wu
Journal:  Metabolism       Date:  2009-11-18       Impact factor: 8.694

Review 8.  Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis.

Authors:  Daniel Walcher; Nikolaus Marx
Journal:  Semin Immunopathol       Date:  2009-04-05       Impact factor: 9.623

9.  C-Peptide in the vessel wall.

Authors:  Daniel Walcher; Nikolaus Marx
Journal:  Rev Diabet Stud       Date:  2009-11-10

10.  Activation of the non-receptor tyrosine kinase cSrc in macrophage-rich atherosclerotic plaques of human carotid arteries.

Authors:  Sono Toi; Noriyuki Shibata; Tatsuo Sawada; Makio Kobayashi; Shinichiro Uchiyama
Journal:  Acta Histochem Cytochem       Date:  2007-12-21       Impact factor: 1.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.